secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verastem, Inc. (VSTM)
CIK:        0001526119
Form:       8-K
Filed at:   2026-06-23T20:02:33+00:00
Accession:  0001104659-26-076809
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verastem's VS-7375 shows 93% CA19-9 reduction in PDAC; plans Phase 3 in 1H2027
------------------------------------------------------------------------------

- 93% (13/14) of heavily pretreated mPDAC patients at 900mg QD achieved >50% reduction in CA19-9; all remain on treatment.
- VS-7375 900mg QD achieved target plasma levels with clear PK separation from 600mg; safety profile favorable with low-grade GI AEs attenuating after cycle 1.
- Dose-dependent anti-tumor activity across PDAC, mCRC, and NSCLC; combination with cetuximab or Gem/NabP shows combinability without overlapping toxicities.
- Intends to collaborate with Erasca (ERAS) to evaluate VS-7375 + ERAS-0015 in preclinical models; future clinical trial collaboration possible.
- Key milestones: complete Phase 1/2 enrollment by June 2026; first patient in Phase 2 registration trials mid-2026; FDA meeting by end of 2026; Phase 3 start 1H2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1526119/000110465926076809/0001104659-26-076809-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1526119/000110465926076809/tm2618546d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-076809

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer